Apoptosis induction by quinazoline-derived alpha1-blockers in prostate cancer cells: biomolecular implications and clinical relevance.
In patients with androgeri-sensitive prostate cancer androgen-deprivation therapy leads to apoptosis of hormone-dependent cells but it may select out androgen-refractory clones. The apoptosis of prostate cancer cells induced by quinazoline-derived alpha1-adrenoceptor antagonists (doxazosin, terazosin, prazosin) counteracts cell proliferation and may have the potential of reversing or delaying prostate cancer growth. Elucidation of the biomolecular mechanisms whereby quinazoline-alpha1-adrenoceptor-antagonists are able to induce anoikis and apoptosis in androgen-refractory prostate cancer cells would be favorable for designing effective therapeutic regimens in the management of advanced prostate cancer.
Alberti
C
C
Surgical Semeiotics, University of Parma, Italy.
D058668:Adrenergic alpha-1 Receptor Antagonists; D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011799:Quinazolines / Q000494:pharmacology* / Q000627:therapeutic use
D058668:Adrenergic alpha-1 Receptor Antagonists; D051017:Apoptosis Regulatory Proteins; D011799:Quinazolines